"Canadian Consensus on Measures and Assessments in Mobility, Exercises and Cognition in the Elderly. From the CIHR-CCNA"

Thursday, April 16th, 2015

Salon H, Hotel Bonaventure, Montreal, QC

A Theme In A Day

Manuel Montero-Odasso MD, PhD, AGSF, FRCPC





Canadian Consortium on Neurodegeneration in Aging. The Canadian Component of CIHR's International Collaborative Research Strategy for Alzheimer's Disease.





What makes a person look old?



- Slow Gait
- Mental Slowing



Mobility and Cognition in Seniors. Report from the 2008 Institute of Aging (CIHR) Mobility and Cognition Workshop.

Manuel Montero-Odaso M, (MD, PhD, AGSF, FRCPC)^{1,2,3}; Louis Bherer, (MSc, PhD)⁴;
 Stephanie Studenski , (MD, MPH, AGSF)⁵; Karen Gopaul, (MSc.)¹; Afua Oteng-Amoako, (MSc.)¹; Sarah Woolmore-Goodwin (MSc), Paul Stoole, (PhD)⁶; Jennie Wells, (MD, FRCPC,FACPA)²; Timothy Doherty , (MD, PhD, FRCPC)⁶; Aleksandra A Zecevic ⁷, (PhD);
 David Galinsky ⁸ (MD), R. Jane Rylett, (PhD, FCAHS)⁹; Jeffrey Jutai¹⁰, (PhD); Susan Muir – Hunter^{1,7}, (PT, PhD); Mark Speechley, (PhD); Richard Camicioli , (MD, FRCPC)¹¹.


Canadian Geriatric Journal, 2015 (in press)



PROGRESS IN GERIATRICS

Gait and Cognition: A Complementary Approach to Understanding Brain Function and the Risk of Falling

Manuel Montero-Odasso, MD, PhD, AGSF, *[†] Joe Verghese, MB, BS,[‡] Olivier Beauchet, MD, PhD,[§] and Jeffrey M. Hausdorff, PhD^{#**}





AMERICAN GERIATRICS

SOCIETY






Figure 1 Conceptual Framework of Cognitive and Mobility decline. Modified from^{1;7}

Spectrum of cognitive and mobility decline in aging

Note: DTC: dual-task gait cost





Canadian Consortium

on Neurodegeneration in Aging

The Canadian Component of CIHR's International Collaborative Research Strategy for Alzheimer's Disease.

CCNA Motor, Exercise & Cognition (MEC) Team



Distinctive expertise in exercise interventions gait/physical activity cognition

Including 2 Canada Research Chairs

Teresa Liu-Ambrose (UBC)

Richard Camicioli (U of Alberta)

Bill McIlroy (U of Waterloo/Toronto) Quincy Almeida (Laurier U) Laura Middleton (U of Waterloo) Manuel MonteroOdasso (Western) Susan Hunter Akshya Vasudev Amer Burham Mark Speechley

Louis Bherer (Concordia U) Julien Doyon (U de Montreal) Karen Li (Concordia U) Jose Morais Sarah Fraser (McGill U)

MEC Team 12 Motor, Exercise and Cognition

Leader: Manuel Montero Odasso Co-Leader: Louis Bherer

Objectives and Deliverables

1- Developing Understanding (years 1-2)

- To develop common tools, language and outcomes measures for motor & cognition
- To understand the anatomical substrate of motor & cognition (imaging, biomarkers)
 Deliverable: we will create the "Canadian Consensus on Mobility and Cognition"

•2- Applying Understanding (years 2-5)

- •To conduct a phase II **multimodal clinical trial** using exercises + cognitive remediation + Vitamin D to improve cognition in SCI-MCI
- •To translate motor assessments in cognitive clinics as a complementary diagnostic tool for Dementia risk stratification

•To translate exercise intervention to improve cognition in the real world




Motor, Exercise and Cognition Team-CCNA Team 12 version 2 A complementary window to understand and treat AD and Neurodegenerative Disease of Aging

	Developing understanding Gait & Cognition & Exercise		Applying understanding Assessment/Interventions	
Deliverables	1-Developing tools, techniques and common language in Gait & Cognition and Motor learning	2-Characterize the "Motor Signature" of cognitive decline in "network" diseases as a new biomarker	3-Advance diagnostic and research tools	4-Advance therapeutic strategies: RCT
Projects	 1A – Evidence, diagnostics, interventions and outcomes linking gait, cognition, motor learning, exercise and brain health (Year 1) 1B – Mobility/walking competency, cognition, motor learning and physical activity among older adults (Normal, MCI, AD) (Year 1) 	 2A – Dual task paradigm in gait-cognition cohort studies 2B – Vascular & genomics components in network diseases affecting gait & cognition. Role of depression, vitamin D and inflammation. 2C– Frontal-executive, motor function and learning with aging (Years 1-3) 	 3A – Optimal exercise interventions and logistic of Synergic Trial (Years 1) 3B – Indices of vascular health that relate to impairment of gait and cognition (Years 2-5) 3C- Imaging variables. Blood test (years 1, 3, 5) 	4A – Exercise + Vitamin D+ Cognitive remediation interventional trial (Years 2 - 5)
Methods	Systematic reviews, consensus panels, technology development, Identification of mediators and moderators	Cross-sectional & prospective studies across the spectrum of mobility and cognition	a-Prospective cohort studies b-Pilot the logistic of the SYNERGIC Trial. MRI/Blood/	SYNERGIC Trail Phase II clinical trial combining Exercise+Vit D+ Cognitive ReMeds.
	 Cross team supervision of Interaction with Carol Green 	ture (imaging), genotyping, inflamn graduate student and research fell enwood's team : Nutrition and exe	ows	lar illness and impacts, Dr

Richard Camicioli's team: Lewy Bodies and Dementia, Dr Sylvie Belleville's team: Cognitive Intervention and Brain Plasticity, Roger Dixon's team: Developing New Biomarkers, Dr. Natalie Philips' team: Interventions at the Sensory and Cognitive Interface, Dr Michael Borrie's cohort platform and Drs Alan Evans, Louis Collins & Simon Duchesne's team: Imaging/Database/Information Technology Platform.



Gait as a biomarker of cognitive decline



Jack CR et al. Lancet Neurology 2010

Dynamic biomarkers of the Alzheimer's pathological cascade

A β is identified by CSF A β_{42} or PET amyloid imaging. Tau-mediated neuronal injury and dysfunction is identified by CSF tau or fluorodeoxyglucose-PET. Brain structure is measured by use of structural MRI. A β = β -amyloid. MCI=mild cognitive impairment.



Objectives:

1-Identify and establish common nomenclature and assessments for cognition/motor interaction older adults.

2-Propose a set of "core mobility and cognitive tests" to assess cognitive and mobility interactions and to be used as outcomes for interventions.

3-Identify the best mobility assessment to be used as a complementary diagnostic tool for detecting dementia.

4-Identify the best cognitive assessment to be used as a complementary diagnostic tool for detecting seniors at risk of dysmobility, falls and fractures.

5-Identify cutting edge research being done by trainees across Canada, highlighted during the consensus session through posters presentations.

6-Foster national and international collaborations and data sharing based on the core assessment battery selected by consensus.



Acknowledgments



Gait & Brain Team Parkwood Institute, London ON

Karen Gopaul Dr Susan Muir Lynden Rodrigues **Brittany Barnes** Jon Snir **Elvse Gordon**





Jose Morais CGS Secretariat

Abstract Judges

Julien Dovon Susan Hunter Louis Bherer Manuel MonteroOdasso

Advisory Board

Stephanie Studenski Caterina Rosano Jeffrey Hausdorff Joe Verghese **Olivier Beauchet**

for the MEC TEAM

Richard camicioli Mark Speechley Amer Burhan Akshya Vasudev Karen Li Teresa Liu-Ambrose Laura Middleton **Bill Mcllroy**



Funding Agencies

Canadian Institute of Health & Research Ontario Ministry of Research and Innovation The Physicians Services Incorporated

The Drummond Foundation Lawson Health Research Institute







PSI FOUNDATION







Canadian Consortium on Neurodegeneration in Aging The Canadian Component of CIHR's International Collaborative Research Strategy for Alzheimer's Disease.

